Expression of the melanoma-associated antigen is associated with progression of human thyroid cancer

Endocrine-Related Cancer

Volumn 16, Issue 2, 2009, Pages 455-466

  Cheng, Sonia ^a,b   Liu, Wei ^a   Mercado, Moises ^b   Ezzat, Shereen ^a   Asa, Sylvia L ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

MELANOMA ANTIGEN; PROTEIN P53; MAGEA3 PROTEIN, HUMAN; MAGEA6 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CANCER INVASION; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; THYROID CANCER; TISSUE MICROARRAY; WESTERN BLOTTING; ADOLESCENT; ADULT; AGED; CELL NUCLEUS; CYTOPLASM; ENZYME IMMUNOASSAY; FEMALE; MALE; METABOLISM; METASTASIS; MIDDLE AGED; PAPILLARY CARCINOMA; PATHOLOGY; SURVIVAL RATE; THYROID GLAND; THYROID TUMOR;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CARCINOMA, PAPILLARY; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; SURVIVAL RATE; THYROID GLAND; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 67650482954     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1677/ERC-09-0002     Document Type: Article

References (27)

1. Asa SL 2005 The role of immunohistochemical markers in the diagnosis of follicular-patterned lesions of the thyroid. Endocrine Pathology 16 295-309.
2. St Bernard R, Zheng L, Liu W, Winer D, Asa SL & Ezzat S 2005 Fibroblast growth factor receptors as molecular targets in thyroid carcinoma. Endocrinology 146 1145-1153.
3. Bourdon JC 2007 p53 Family isoforms. Current Pharmaceutical Biotechnology 8 332-336.
4. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK & Lane DP 2005 p53 isoforms can regulate p53 transcriptional activity. Genes and Development 19 2122-2137.
5. Chitale DA, Jungbluth AA, Marshall DS, Leitao MM, Hedvat CV, Kolb D, Spagnoli GC, Iversen K & Soslow RA 2005 Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Modern Pathology 18 119-126.
6. Donghi R, Longoni A, Pilotti S, Michieli P, Della Porta G & Pierotti MA 1993 Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland. Journal of Clinical Investigation 91 1753-1760.
7. Fagin JA, Matsuo K, Karmakar A, Chen DL, Tang SH & Koeffler HP 1993 High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. Journal of Clinical Investigation 91 179-184.
8. Fischer C, Gudat F, Stulz P, Noppen C, Schaefer C, Zajac P, Trutmann M, Kocher T, Zuber M, Harder F et al. 1997 High expression of MAGE-3 protein in squamous-cell lung carcinoma. International Journal of Cancer 71 1119-1121.
9. Hosal SA, Apel RL, Freeman JL, Azadian A, Rosen IB, LiVolsi VA & Asa SL 1997 Immunohistochemical localization of p53 in human thyroid neoplasms: correlation with biological behavior. Endocrine Pathology 8 21-28.
10. Hudolin T, Juretic A, Pasini J, Tomas D, Spagnoli GC, Heberer M, Dimanovski J & Kruslin B 2006 Immunohistochemical expression of tumor antigens MAGE-A1, MAGE-A3/4, and NY-ESO-1 in squamous cell carcinoma of the penis. Urology 68 205-207.
11. Ito T, Seyama T, Mizuno T, Tsuyama N, Hayashi T, Hayashi Y, Dohi K, Nakamura N & Akiyama M 1992 Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Research 52 1369-1371.
12. Jang SJ, Soria JC, Wang L, Hassan KA, Morice RC, Walsh GL, Hong WK & Mao L 2001 Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Research 61 7959-7963.
13. Kobayashi Y, Higashi T, Nouso K, Nakatsukasa H, Ishizaki M, Kaneyoshi T, Toshikuni N, Kariyama K, Nakayama E & Tsuji T 2000 Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. Journal of Hepatology 32 612-617.
14. Kondo T, Ezzat S & Asa SL 2006 Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nature Reviews. Cancer 6 292-306.
15. Kondo T, Zheng L, Liu W, Kurebayashi J, Asa SL & Ezzat S 2007a Epigenetically controlled fibroblast growth factor receptor 2 signaling imposes on the RAS/BRAF/mitogen-activated protein kinase pathway to modulate thyroid cancer progression. Cancer Research 67 5461-5470.
16. Kondo T, Zhu X, Asa SL & Ezzat S 2007b The cancer/testis antigen melanoma-associated antigen-A3/A6 is a novel target of fibroblast growth factor receptor 2-IIIb through histone H3 modifications in thyroid cancer. Clinical Cancer Research 13 4713-4720.
17. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S & Asa SL 2007 CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 26 2747-2758.
18. Liu W, Cheng S, Asa SL & Ezzat S 2008 The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Research 68 8104-8112.
19. Milkovic M, Sarcevic B & Glavan E 2006 Expression of MAGE tumor-associated antigen in thyroid carcinomas. Endocrine Pathology 17 45-52.
20. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, Rodolfo M & Schneider C 2006 MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. PNAS 103 11160-11165.
21. Picard V, Bergeron A, Larue H & Fradet Y 2007 MAGE-A9 mRNA and protein expression in bladder cancer. International Journal of Cancer 120 2170-2177.
22. Stromberg S, Björklund MG, Asplund C, Skollermo A, Persson A, Wester K, Kampf C, Nilsson P, Andersson AC, Uhlen M et al. 2007 A high-throughput strategy for protein profiling in cell microarrays using automated image analysis. Proteomics 7 2142-2150.
23. Toledo F & Wahl GM 2006 Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nature Reviews. Cancer 6 909-923.
24. Tsuneyama K, Sasaki M, Shimonishi T & Nakanuma Y 2004 Expression of MAGE-A3 in intrahepatic cholangiocarcinoma and its precursor lesions. Pathology International 54 181-186.
25. Vrolijk H, Sloos W, Mesker W, Franken P, Fodde R, Morreau H & Tanke H 2003 Automated acquisition of stained tissue microarrays for high-throughput evaluation of molecular targets. Journal of Molecular Diagnostics 5 160-167.
26. Yang B, O'Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann FM et al. 2007 MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Research 67 9954-9962.
27. Zhu X, Asa SL & Ezzat S 2008 Fibroblast growth factor 2 and estrogen control the balance of histone 3 modifications targeting MAGE-A3 in pituitary neoplasia. Clinical Cancer Research 14 1984-1996.